Alkermes is rated Buy as LUMRYZ momentum, LYBALVI trends, and pipeline progress drive growth despite near-term profit pressure. Click for more on ALKS stock.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Baird Equity Asset Management recently released its “Small/Mid Cap Growth Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund benefited from a sharp rebound in the broader equity market during the second quarter of 2026, as improving corporate earnings, resilient economic growth, moderating inflation, and continued artificial intelligence […]
Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult ADHD Investigator Symptom Rating Scale were 14 points at a total daily dose of 20 mg and 19 points at 50 mg. Both […]
In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult ADHD symptoms over 14 days with a generally well-tolerated safety profile. These data represent the first clinical evidence of an orexin receptor agonist’s effects in ADHD, potentially widening Alkermes’ orexin franchise beyond sleep disorders and other...
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.
Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.
Alkermes plc (NASDAQ:ALKS) shares gained 6. 5% on Monday after the company reported positive Phase 1b clinical trial results for ALKS 7290, an investigational treatment for adults with attention-deficit hyperactivity disorder (ADHD).
ALKS stock slid 7% to a June low as healthcare peers fell.
Detailed price information for Alkermes Plc (ALKS-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.